Sugi Predict

Sugi Predict / Compounds / SCHEMBL346869

SCHEMBL346869

SCHEMBL346869

OC[C@H]1OC(OC[C@@]2(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.76

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 1/20 0.76
▸ CCNB1 P14635 1/20 0.76
▸ CA2 P00918 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ TYR P14679 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ LDHA P00338 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7736074 1.00 CDK1 (0.76) CDK1CCNB1CA2CA9MEN1
SCHEMBL181304 1.00 CDK1 (0.76) CDK1CCNB1CA2CA9MEN1
SCHEMBL4762882 1.00 CDK1 (0.76) CDK1CCNB1CA2CA9MEN1
SCHEMBL914447 1.00 CDK1 (0.76) CDK1CCNB1CA2CA9MEN1
SCHEMBL4764191 1.00 CDK1 (0.76) CDK1CCNB1CA2CA9MEN1
SCHEMBL29524904 0.96 CDK1 (0.83) CDK1CCNB1CA2CA9MEN1
SCHEMBL875991 0.90 CDK1 (0.66) CDK1CCNB1CA2CA9MEN1
SCHEMBL2808642 0.89 CDK1 (0.64) CDK1CCNB1CA2CA9MEN1
SCHEMBL5081419 0.88 CDK1 (0.61) CDK1CCNB1CA2CA9MEN1
Raffinose SCHEMBL23549944 0.88 CDK1 (0.97) CDK1CCNB1CA2CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3480134-B1 FRUIT AND VEGETABLE PACKAGING MATERIAL FUJIFILM CORP (JP) 2024-08-14 — — EP claimed
US-9957488-B2 Pharmaceutical compositions and dermatogic compositions synthesized from catalytic domains producing highly α1,2 branched dextrans INSITUT NATIONAL DES SCIENCES APPLIQUEES (INSA) (FR) 2018-05-01 — — US claimed
EP-2012149-B1 RETARDATION FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY KONICA MINOLTA OPTO INC (JP) 2018-02-14 — — EP claimed
US-20170326096-A1 Selective Targeting of Procoagulant Platelets NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2017-11-16 — — US claimed
US-9688968-B2 Prebiotic composition or pharmaceutical composition synthesized from catalytic domains producing highly alpha-1,2 branched dextran INSTITUT NATIONAL DES SCIENCES APPLIQUEES (INSA) (FR) 2017-06-27 — — US claimed
US-20170152489-A1 Prebiotic composition or pharmaceutical composition synthesized from catalytic domains producing highly alpha-1,2 branched dextran INSTITUT NATIONAL DES SCIENCES APPLIQUEES (INSA) (FR) 2017-06-01 — — US claimed
US-9598595-B2 Retardation film, polarizing plate and liquid crystal display device Konica Minolta, Inc. (JP) 2017-03-21 — — US claimed
US-20160137867-A1 RETARDATION FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE Konica Minolta, Inc. (JP) 2016-05-19 — — US claimed
US-20150086525-A1 PREBIOTIC COMPOSITION OR PHARMACEUTICAL COMPOSITION SYNTHESIZED FROM CATALYTIC DOMAINS PRODUCING HIGHLY ALPHA-1,2 BRANCHED DEXTRAN INST NAT SCIENCES APPLIQ (FR) 2015-03-26 — — US claimed
US-8758744-B2 Prebiotic composition or pharmaceutical composition synthesized from catalytic domains producing highly α-1,2 branched dextran INSTITUT NATIONAL DES SCIENCES APPLIQUEES (INSA) (FR) 2014-06-24 — — US claimed
US-20070254115-A1 Polarizer protective film, manufacturing method thereof, polarizing plate and liquid crystal display KONICA MINOLTA OPTO, INC. (JP) 2007-11-01 — — US claimed
EP-1828407-A1 ASSAY FOR DETERMINATION OF FREE D-GALACTASE AND/OR L-ARABINOSE Megazyme IP Limited (IE) 2007-09-05 — — EP claimed
US-20060166208-A1 Induction of the mitochondrial permeability transition NEW SOUTH INNOVATIONS PTY LIMITED (AU) 2006-07-27 — — US claimed
WO-2006064487-A1 ASSAY FOR DETERMINATION OF FREE D-GALACTASE AND/OR L-ARABINOSE MEGAZYME IP LIMITED (IE) 2006-06-22 — — WO claimed
EP-1563099-A1 INDUCTION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION Unisearch Limited, University of New South West (AU) 2005-08-17 — — EP claimed
WO-2004042079-A1 INDUCTION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION UNISEARCH LIMITED (AU) 2004-05-21 — — WO claimed
CN-1094153-C Process of preparation for galactosyl sucrose — 2002-11-13 — — CN claimed
EP-1111065-A2 Production of saccharide carboxylic acids TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-27 — — EP claimed
CN-1265596-A isoflavone-containing composition OTSUKA PHARMA CO LTD (JP) 2000-09-06 — — CN claimed
CN-1253182-A Process of preparation for galactosyl sucrose SHIOMIZUMINATO REFINED SUGAR C (JP) 2000-05-17 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166208-A1 Induction of the mitochondrial permeability transition TFAM, NME4, TIMM50 CDK1 422/4885CCNB1 394/4885CA2 1935/4885
US-20170326096-A1 Selective Targeting of Procoagulant Platelets SELP, MPL, PLAT CDK1 1228/4885CCNB1 2156/4885CA2 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.